James B. Yu, MD, on RTOG 0415: Fractionation Schedules in Patients With Low-Risk Prostate Cancer
2015 ASTRO Annual Meeting
James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk prostate cancer (Abstract LBA6).
Jay Harris, MD
Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses the difficulty reconciling recent important trials on radiotherapy for breast cancer: The Z11 trial suggested that breast tangents are sufficient, while MA.20 and EORTC studies suggested that full nodal irradiation is beneficial.
Robert Kuske, MD
Robert Kuske, MD, of Arizona Breast Cancer Specialists, discusses the evaluation of more than 1,300 patients with accelerated partial-breast irradiation via multicatheter interstitial brachytherapy, focusing on toxicity and cosmetic outcomes (Abstract 133).
Anthony Zietman, MD
Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).
Bruce Minsky, MD
ASTRO President Bruce Minsky, MD, of MD Anderson Cancer Center, talks about the goals and highlights of this year’s ASTRO Annual Meeting.
Supriya Chopra, MD
Supriya Chopra, MD, of Tata Memorial Hospital, discusses results of the PARCER study, which compared conventional 3D conformal radiotherapy to image-guided intensity-modulated radiotherapy in reducing bowel side effects for women with cervical cancer (Abstract 8).